Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncothyreon has filed an investigational new drug application with the FDA for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for the treatment of advanced cancers.
Subscribe to our email newsletter
Following FDA review of this investigational new drug application (IND), the company plans to initiate a Phase I clinical trial of PX-866.
Robert Kirkman, president and CEO of Oncothyreon, said: “This IND for PX-866 demonstrates the continued advancement of Oncothyreon’s small molecule oncology pipeline. In addition to the planned trial of PX-866, Oncothyreon is currently conducting a Phase II trial of PX-12, a small molecule inhibitor of thioredoxin-1, in patients with advanced pancreatic cancer and a Phase I trial of PX-478, a small molecule inhibitor of HIF-1 alpha, in patients with advanced solid tumors or lymphomas.”